Emerging Growth NewswireMed, Biotech & Pharma 22nd Century Group, Inc. (NASDAQ: XXII) Emerging Growth Research Report – April 9, 2025 By admin - FacebookXPinterestWhatsApp Launchpad: Q4:24 revenue missed expectations as 2024 CMO customer attrition continued due to price hikes. Management believes attrition is now complete and that CMO operations have stabilized in Q1:25.